Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2026)
Ultragenyx Pharmaceutical (RARE) reported EBITDA Margin of -31.31% for Q2 2026, up 27.97 percentage points from -59.28% a year earlier and up 87.07 percentage points from the prior quarter.
Powered by 
Analysis
Ultragenyx Pharmaceutical (RARE) EBITDA Margin (2016 - 2026) Analysis & Trends
Over the twelve months ended Jun 30, 2026, Ultragenyx Pharmaceutical's EBITDA Margin came in at -69.04%, up 7.83 percentage points year-over-year; for FY2025, it was -74.29%, up 14.99 percentage points from FY2024.
- EBITDA Margin has increased for three consecutive years, with a five-year change of +42.98 percentage points (FY2020 to FY2025).
- By year, EBITDA Margin came in at -89.29% in FY2024 (+35.83 pp), -125.12% in FY2023 (+48.47 pp), -173.59% in FY2022 (-68.73 pp) and -104.86% in FY2021 (+12.41 pp).
- The Q2 2026 figure ranks as the highest quarterly EBITDA Margin in data going back to Q2 2016.
- Year over year, EBITDA Margin gained in six of the last eight quarters, with an average year-over-year change of +18.14 percentage points.
- The high point for year-over-year EBITDA Margin in five years was Q3 2023 (a gain of 102.31 percentage points); the low point was Q3 2022 (a drop of 136.88 percentage points).
- Per Business Quant data, the three quarters before Q2 2026 came in at -118.38% (Q1 2026), -50.41% (Q4 2025) and -101.71% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 645.01 Bn | 563.54 Bn | 17.26 Bn | 35.95% |
| 2 | AbbVie | 465.23 Bn | 438.39 Bn | 12.70 Bn | 49.01% |
| 3 | Merck | 368.40 Bn | 322.83 Bn | 12.21 Bn | 6.02% |
| 4 | Novartis Ag | 278.02 Bn | 233.89 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 254.57 Bn | 228.13 Bn | 12.86 Bn | 33.11% |
| 6 | Amgen | 229.02 Bn | 184.42 Bn | 7.24 Bn | 46.01% |
| 7 | Gilead Sciences | 187.74 Bn | 161.85 Bn | 6.22 Bn | -124.26% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | 39.16% |
| 9 | Vertex Pharmaceuticals | 133.45 Bn | 105.45 Bn | 2.84 Bn | 39.10% |
| 10 | Ultragenyx Pharmaceutical | 1.51 Bn | -292.70 Mn | 180.00 Mn | -31.31% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -31.31% |
| Mar 31, 2026 | -118.38% |
| Dec 31, 2025 | -50.41% |
| Sep 30, 2025 | -101.71% |
| Jun 30, 2025 | -59.28% |
| Mar 31, 2025 | -96.40% |
| Dec 31, 2024 | -68.49% |
| Sep 30, 2024 | -88.34% |
| Jun 30, 2024 | -73.12% |
| Mar 31, 2024 | -143.80% |
| Dec 31, 2023 | -89.37% |
| Sep 30, 2023 | -140.65% |
| Jun 30, 2023 | -131.66% |
| Mar 31, 2023 | -148.13% |
| Dec 31, 2022 | -136.11% |
| Sep 30, 2022 | -242.96% |
| Jun 30, 2022 | -153.47% |
| Mar 31, 2022 | -165.81% |
| Dec 31, 2021 | -118.76% |
| Sep 30, 2021 | -106.08% |
API Access
Ultragenyx Pharmaceutical EBITDA Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RARE&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "ebitda-margin", "ticker": "RARE", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=ebitda-margin&ticker=RARE&period=max&api_key=YOUR_API_KEY");
const data = await res.json();